Since the U.S. Food and Drug Administration’s (FDA) approval of the first commercial systems in 2000, digital mammography has become an accepted standard of care in breast cancer screening and diagnosis and has paved the way for the newest groundbreaking technology in this arena – breast tomosynthesis.
Breast tomosynthesis is a three-dimensional imaging technology that involves acquiring images of a stationary compressed breast at multiple angles during a short scan. The individual images are then reconstructed into a series of thin high-resolution slices that can be displayed individually or in a dynamic ciné mode.
Design Considerations in Optimizing a Breast Tomosynthesis System
Breast tomosynthesis, also referred to as three-dimen- sional (3D) mammography, has been available for clinical use in numerous countries outside of the United States (U.S.) since 2009. In February 2011, the U.S. Food and Drug Administration (FDA) approved the Hologic Selenia® Dimensions® 3D (breast tomosynthesis) system, making it the first, and currently, the only commercially available breast tomosynthesis system in the U.S. As such, interest in the area of breast tomosynthesis has grown tremendously.